In addition to resistance to EGFR-TKIs, MDM2 amplification was also confirmed to be associated with the insensitivity to radiotherapy (Feng et al. 2016; Koom et al. 2012) and the hyperprogressive disease (HPD) associated with cancer immunotherapy (Kato et al. 2017). The gene discussed is MDM2; the disease is cancer.